Cite

HARVARD Citation

    Ma, C. et al. (2014). Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Alimentary pharmacology & therapeutics. 40 (9), pp. 1044-1055. [Online]. 
  
Back to record